<DOC>
	<DOCNO>NCT00016406</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether combination chemotherapy effective without filgrastim treat breast cancer . PURPOSE : Randomized phase III trial compare effectiveness combine doxorubicin , cyclophosphamide , paclitaxel without filgrastim treat woman inflammatory locally advanced breast cancer .</brief_summary>
	<brief_title>S0012 Doxorubicin , Cyclophosphamide , Paclitaxel With Without Filgrastim Treating Women With Inflammatory Locally Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare microscopic pathologic response rate woman inflammatory locally advanced breast cancer treat standard neoadjuvant doxorubicin cyclophosphamide follow weekly paclitaxel vs weekly doxorubicin daily oral cyclophosphamide filgrastim ( G-CSF ) follow weekly paclitaxel . - Compare toxic effect regimens patient population . - Compare deliver dose intensity regimens patient population . - Evaluate association microscopic pathologic complete response clinical complete response primary tumor site patient . OUTLINE : This randomize , multicenter study . Patients stratify accord disease status ( inflammatory v ) . Patients randomize one two treatment arm . - Arm I : Patients receive doxorubicin IV follow cyclophosphamide IV day 1 . Treatment repeat every 21 day total 5 course absence disease progression unacceptable toxicity . Three week completion doxorubicin cyclophosphamide , patient receive paclitaxel IV 1 hour weekly day 1 total 12 week . - Arm II : Patients receive doxorubicin IV day 1 , oral cyclophosphamide day 1-7 , filgrastim ( G-CSF ) subcutaneously day 2-7 . Treatment repeat weekly total 15 course doxorubicin cyclophosphamide 16 course G-CSF absence disease progression unacceptable toxicity . One week completion G-CSF , patient receive paclitaxel arm I . Within 3-6 week completion chemotherapy , patient stable responsive disease undergo surgical resection tumor affect node . After surgery , patient may receive radiotherapy additional chemotherapy and/or hormonal therapy discretion treat physician . Patients follow every 6 month 1 year annually 4 year . PROJECTED ACCRUAL : A total 350 patient ( 175 per treatment arm ) accrue study within 3 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm inflammatory locally advanced breast cancer Stage IIB ( T3 , N0 , M0 ) , IIIA ( T3 , N12 , M0 T02 , N2 , M0 ) , IIIB ( T4 , N , M0 T , N3 , M0 ) Unresectable otherwise appropriate neoadjuvant therapy Confirmed core needle incisional biopsy Punch biopsy allow invasive disease document No distant metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Not specify Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Renal : Creatinine great ULN Cardiovascular : No congestive heart failure angina pectoris LVEF great low limit normal Other : No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix HIV negative Not pregnant nurse Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy breast cancer Endocrine therapy : No prior hormonal therapy breast cancer Radiotherapy : No prior radiotherapy breast cancer Surgery : No prior definitive surgery breast cancer Other : No concurrent anticancer therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>